[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"lymphoblastic-b-cell-lymphoma\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:lymphoblastic-b-cell-lymphoma":44},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,1,0,[8],{"id":9,"slug":4,"hasResults":10,"nctId":11,"briefTitle":12,"officialTitle":13,"acronym":4,"eligibilityCriteria":14,"healthyVolunteers":10,"sex":15,"minAge":16,"maxAge":17,"enrollmentInfo":18,"targetDuration":4,"studyType":21,"phases":22,"briefSummary":24,"conditions":25,"keywords":28,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":33,"lastUpdatePostDateStruct":34,"startDateStruct":37,"completionDateStruct":39,"leadSponsor":41,"locationsCount":5},"100464869",false,"NCT05333302","Pilot CAR-T Cells Therapy for Children\u002FYoung Adults With CD19+ R\u002FR Leukemia\u002FLymphoma","Pilot Study of CD19 CAR-T Cells Therapy for Relapsed or Refractory Acute Lymphoblastic Leukemia\u002FLymphoma in Children\u002FYoung Adults","Inclusion Criteria:\n\n* CD19+ relapsed or refractory lymphoblastic leukemia\u002Flymphoma;\n* Karnofsky or Lansky performance scale greater or equal to 70;\n* T-cells count in peripheral blood \\>150 cells\u002FµL;\n* Written informed consent.\n\nExclusion Criteria:\n\n* primary immunodeficiencies or genetic syndromes;\n* neurologic diseases;\n* autoimmune diseases or polyallergie;\n* transfusion of donor lymphocyte less than 6 week before CAR-T cells infusion;\n* GvHD grade 2-4;\n* uncontrolled systemic infection;\n* hypoxia (Sp02\\\u003C90%)\n* severe hepatic dysfunction: ALT or AST \\>=3x upper limit of normal for age;\n* renal dysfunction: serum creatinine level \\>=3x upper limit of normal for age;\n* positive serology for human immunodeficiency virus (HIV), active hepatite C or B;\n* pregnancy.","ALL","1 Year","30 Years",{"count":19,"type":20},10,"ESTIMATED","INTERVENTIONAL",[23],"PHASE1","The purpose of this study is to estimate the safety and the efficacy of CAR- T cells immunotherapy for children\u002Fyoung adults with relapsed or refractory acute lymphoblastic leukemia\u002Flymphoma.",[26,27],"B-cell Acute Lymphoblastic Leukemia","Lymphoblastic B-Cell Lymphoma",[29,30,31],"immunotherapy","CAR-T cells","CD19","RECRUITING","2024-08-27",{"date":35,"type":36},"2024-08-28","ACTUAL",{"date":38,"type":36},"2020-10-26",{"date":40,"type":20},"2025-06",{"name":42,"class":43},"Belarusian Research Center for Pediatric Oncology, Hematology and Immunology","OTHER",""]